Canagliflozin, senescent cells and aging in mice: what the study suggests
A study in mice published in Nature Aging links the effect of canagliflozin, a diabetes medicine, to the removal of senescent cells. The findings are early, come from animals, and do not show anything about people.
Source: Diabetes drug canagliflozin and senescent cell removal in mice (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
The study, published in the journal Nature Aging and carried out in mice, looked at canagliflozin, a medicine used to treat type 2 diabetes. According to the description of the study, the researchers linked the drug's effect on the animals' lifespan to the removal of senescent cells, which are cells that stop dividing and build up with age. The biological pathway pointed to involves the substance AICAR and the activation of a protein called AMPK, which helps control cell metabolism.
This kind of research is done in animals and is often an early step in studying biological processes. Results in mice do not always hold up in humans, and the link between senescent cells and healthy aging is still being studied. The claim reached the public through a social media post that said the findings applied to people; the study itself does not prove that.
What it means
The study suggests a possible mechanism linked to aging in mice, involving the removal of senescent cells. It is not yet known whether this effect occurs in people, or whether canagliflozin would have any impact on human aging.
How to read it with care
This result does not replace a medical consultation. Anyone considering a change in diet, supplements or treatment should talk to a doctor or another qualified health professional.